iiinova — where your digital self keeps evolving

Reposted by Alfredo Addeo

ESMO - European Society for Medical Oncology @myesmo.bsky.social · 17/11/2025

👉 Submit an abstract to the European Lung Cancer Congress 2026! Share your research at this leading multidisciplinary congress and drive innovation in the field of thoracic oncology. #esmomeetings #ELCC26 ⏰ Submission deadline: 13 January 2026. 🔗 ow.ly/YEJp50Xomo0

022

Reposted by Alfredo Addeo

ESMO - European Society for Medical Oncology @myesmo.bsky.social · 21/10/2025

#ESMO25: Paradigm shifts are occurring in the management of metastatic mutated #NSCLC. Alfredo Addeo describes some of the innovative #TargetedTherapies and combinations that are improving patient outcomes. #ESMODailyReporter ➡️ ow.ly/IWOr50XeTfh #LungCancer Alfredo Addeo

042

Reposted by Alfredo Addeo

ESMO - European Society for Medical Oncology @myesmo.bsky.social · 13/06/2025

Two studies investigating efficacy of bispecific T-cell engager tarlatamab and lurbinectedin–atezolizumab combination met their primary endpoints of survival. Read the opinion by @alfdoc2.bsky.social‬ in the #ESMODailyReporter 🔗 buff.ly/3NXrdAg #SCLC #LungCancer

021

Alfredo Addeo @alfdoc2.bsky.social · 10/05/2025

Great day one at the 4th #ISLC25 in Rome

000

Reposted by Alfredo Addeo

IASLC @iaslc.bsky.social · 11/04/2025

Don't miss the new #LungCancerConsidered in Italian! @alfdoc2.bsky.social hosts a discussion with Dr. Cecilia Pompili & Dr. Francesco Passiglia to talk about treating resectable Stage III NSCLC & new therapy options. 🎧 Listen now: bit.ly/ItalianVTB #LungCancer #NSCLC #Oncology #VTB

bit.ly

LCC in Italian: Virtual Tumor Board – Resectable Stage III NSCLC | IASLC

As part of IASLC's ongoing series of podcasts in world languages, Dr. Alfredo Addeo moderates a discussion in Italian with Dr. Cecilia Pompili and Dr. Franceso ...

032

Alfredo Addeo @alfdoc2.bsky.social · 16/02/2025

just hot off the press, our review "Primary and Acquired Resistance to Immunotherapy with Checkpoint Inhibitors in NSCLC: From Bedside to Bench and Back". Congrats to all the co-authors , DrBorgeaud Dr Mariniello, Dr Kim, Dr Weiner, Dr Frisone. Here the free access link.springer.com/article/10.1...

link.springer.com

Primary and Acquired Resistance to Immunotherapy with Checkpoint Inhibitors in NSCLC: From Bedside to Bench and Back - BioDrugs

Immunotherapy with checkpoint inhibitors has become the cornerstone of systemic treatment for non-oncogene addicted non-small-cell lung cancer. Despite its pivotal role, a significant proportion of pa...

130

Reposted by Alfredo Addeo

Jarushka Naidoo @drjnaidoo.bsky.social · 13/02/2025

IASLC #WCLC2025 is upon us! Your co-chairs cannot wait to welcome you #NoemiReguart 🇪🇸 #IsabelleOpitz🇨🇭 #UmbertoMalapelle 🇮🇹 & a familiar face from🇮🇪 Registration & abstract submissions are OPEN! Join us in Barcelona | Sept 6–9, 2025 @iaslc.bsky.social @oncoalert.bsky.social #LCSM bit.ly/IASLCWCLC

0105

Reposted by Alfredo Addeo

Tom Newsom-Davis @tnewsomdavis.bsky.social · 07/02/2025

Leaving X I can’t continue to support X with a clear conscience. I hope BlueSky replaces it. But I don’t think it will do so quickly unless we drop X, as opposed to us having feet in both camps.

2113

Reposted by Alfredo Addeo

Tom Newsom-Davis @tnewsomdavis.bsky.social · 31/01/2025

@drsanjaypopat.bsky.social kicks off @btog.bsky.social Essential Update in therapeutic options for stage 4 NSCLC ✅ all topics covered ✅ stellar speaker line up ✅ full house 👊👊👊

162

Reposted by Alfredo Addeo

Tom Newsom-Davis @tnewsomdavis.bsky.social · 31/01/2025

Samreen Ahmed on uncommon EGFR mutations. Referencing the lovely paper & beautiful figure by @alfdoc2.bsky.social Distills treatment options really well

041

Alfredo Addeo @alfdoc2.bsky.social · 29/01/2025

Pleased to share our brand-new certification for our Lung Cancer Centre—a unique quality label within the Canton of Geneva. This achievement has been made possible thanks to an incredible team effort, unwavering commitment, and strong support.#University Hospital Geneva

010

Reposted by Alfredo Addeo

D. Ross Camidge @drcamidge.bsky.social · 13/12/2024

The HTIBM: lessons learned. Episode 6 - Me and Cetnar dance again. @onclive.bsky.social and I were still feeling out what How This is Building Me was a little. I had an evolving people centered model but onclive didn’t want to waste an expert opportunity either.

141

Alfredo Addeo @alfdoc2.bsky.social · 06/12/2024

Lovely team-building karaoke all together—it was so much fun! Special thanks to my Neapolitan friends for singing along to Napul’è!

030

Reposted by Alfredo Addeo

Jarushka Naidoo @drjnaidoo.bsky.social · 29/11/2024

Impact of cycle 1 irAEs on ICI outcomes: - 683pts from SWOG DART trial - g1-2 irAEs = ⬆️OS HR 0.61 p < 0.001 - g3+ irAEs = ⬇️OS HR 1.41 p= .025 - g1-2 derm irAE = ⬆️OS v other g1-2 irAE HR 0.67 p=0.002 Congrats @eladsharonmd.bsky.social @oncoalert.bsky.social academic.oup.com/jnci/advance...

academic.oup.com

First Cycle Toxicity and Survival in Patients with Rare Cancers Treated with Checkpoint Inhibitors

AbstractBackground. Associations between immune-related adverse events (irAEs) from checkpoint inhibitor therapy and outcomes have been previously evaluate

02715

Alfredo Addeo @alfdoc2.bsky.social · 27/11/2024

Dr Filippi shares his thoughts on PCI and RT role at the conference on #SCLC at University Hospital Geneva

000

Alfredo Addeo @alfdoc2.bsky.social · 27/11/2024

Dr Menis kicks off our conference on #SCLC at University Hospital Geneva pleased to have such a great expert here today with us

000

Reposted by Alfredo Addeo

Nathan Pennell MD, PhD, FASCO @n8pennell.bsky.social · 24/11/2024

I know many other have done these but I’ve collected almost 100 people and my personal list is hard to share. go.bsky.app/2mRM9TD

246717